(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Assessment of volumetric IGRT disease response for HNSCC that is treated with definitive CRT is valuable for predicting disease control. Patients with less than 70% volume reduction should be considered for early surgical intervention.

Raj Davuluri, MD, Jeff Krase, PharmD, Michael K. Cheung, MD, Brian N. Allen, MS, Sun K. Yi, MD; Department of Radiation Oncology, University of Arizona Cancer Center

INTRODUCTION: Organ-preserving chemoradiation (CRT) has become standard of care for head and neck squamous cell carcinoma (HNSCC). Volumetric image-guided radiotherapy (IGRT), though primarily utilized for daily setup precision, may also allow for treating physicians to evaluate disease response throughout therapy. In other disease sites, such as lung, IGRT-measured tumor response has been found to be predictive of oncologic outcome. To our knowledge, no such study has been performed in patients treated for HNSCC.

METHODS: After institutional review board (IRB) approval, patients who were treated definitively with CRT for stage III–IV HNSCC on TomoTherapy (Madison, WI) with daily megavoltage cone-beam computed tomography (MVCT) IGRT were retrospectively reviewed for volumetric response. A resident physician (RD), alongside an expert HN radiation oncologist (SY), contoured identifiable disease on representative weekly imaging while blinded to patient outcome. Response was measured against formal posttreatment clinical, radiological, and/or histological assessment. Data were stratified according to primary site or largest nodal disease. Student t-test was utilized to compare percent volume reduction in those with recurrence vs those without recurrence.

RESULTS: Thirty-five patients were identified with a median follow-up of 15.8 months. Fifty-six percent of patients were HPV-positive, and 67% was oropharyngeal, 12% was laryngeal, 9% was hypopharyngeal, and 6% was nasopharyngeal in origin. Twenty-six percent of patients were T4, 26% was T3, 21% was T2, and 17% was T1. Twelve percent of patients were N3, 65% was N2, 6% was N1, and 11% was N0. Eighty-five percent of patients had stage IV disease, and 15% had stage III disease. The median dose to gross disease was 70 Gy in 35 fractions. A total of 6 recurrences at a median follow-up of 8 months [range: ] were identified. Mean percent volume of disease at the end of treatment for those with recurrence vs those without recurrence was significantly different (31% vs 6%; P = .001). For primary tumors, the difference in mean residual disease was 20% vs 5% (P = .005) for recurrences vs nonrecurrences, respectively. For nodal disease, the difference in mean residual disease was 47% vs 6% (P = .0001) for recurrences vs nonrecurrences, respectively. When percent residual disease was less than 30% of original volume, the positive predictive value, negative predictive value, sensitivity, and specificity were 100%, 93%, 66%, and 100%, respectively.

CONCLUSIONS: Assessment of volumetric IGRT disease response for HNSCC that is treated with definitive CRT is valuable for predicting disease control. Patients with less than 70% volume reduction should be considered for early surgical intervention.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content